Patent intelligence · US
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
Patent details — US 2012003230
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 5, 2012
- Expiration
- Dec 31, 2031
- Applicant
- TROGDEN JOHN T [US]
- CPC classes
- A61K 38/ 02 A I, A61K 38/ 16 A I, A61K 39/ 395 A I, A61K/31711
Quick answer
US 2012003230 (SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER) is held by TROGDEN JOHN T [US]. Status: granted. Granted Jan 5, 2012. Expires Dec 31, 2031 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TROGDEN JOHN T [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 02 A I, A61K 38/ 16 A I, A61K 39/ 395 A I, A61K/31711, A61K/393955, A61K/4710
More from TROGDEN JOHN T [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted
Frequently asked questions
What is US patent 2012003230?
US 2012003230 (SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER) is held by TROGDEN JOHN T [US]. Status: granted. Granted Jan 5, 2012. Expires Dec 31, 2031 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2012003230?
TROGDEN JOHN T [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 2012003230 expire?
Our index shows an expiration date of Dec 31, 2031 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.